Glycosmedia Weekly Diabetes News Update
View this email in your browser

Platinum Sponsors:

Boehringer Ingelheim Lilly

Gold Sponsors:

Novo Nordisk

AstraZeneca

Silver Sponsors:
 

Abbott Diabetes Care

Ericas

Glycosmedia Weekly Diabetes News - 07/31/2020

Sodium–Glucose Cotransporter-2 Inhibitors and the Risk for Diabetic Ketoacidosis

SGLT-2 inhibitors were associated with an almost 3-fold increased risk for DKA, with molecule-specific analyses suggesting a class effect (Annals of Internal Medicine)


Limited Evidence for the Health Effects and Safety of Intermittent Fasting Among Patients With Type 2 Diabetes

The value of intermittent fasting compared with other dietary regimens is unclear given the potentially higher risk of adverse events during intermittent fasting, whereas the best, but limited, evidence suggests that the efficacy of intermittent fasting was only noninferior to caloric restriction for hemoglobin A1c improvement and weight loss (JAMA)


Persons with type 2 diabetes and high insulin persistence were associated with a lower risk of mortality

This study showed that patients with ≥90% insulin persistence were associated with lower risks of all‐cause mortality than did patients with <90% insulin persistence (Journal of Diabetes Investigation)


Progression of Diabetic Retinopathy and Declining Renal Function in Patients with Type 2 Diabetes

Declining renal function was independently associated with DR progression in patients with NPDR, suggesting that investigation of DR status should be recommended for patients with declining renal function (Journal of Diabetes Research)


Share
Tweet
Forward
+1
Share
Please visit the Glycosmedia website for more features and information, including:

Journal Watch
Comment on recently published papers written by the medical editors of Glycosmedia.

Diabetes Updates
Updates written by Professor Steve Bain (Diabetologist) and Dr. Mark Freeman (Diabetologist).

Book and Product Reviews
A selection of book and product reviews written by the contributing editors of Glycosmedia.
The Glycosmedia website and newsletter has been made possible with funding support from our sponsors. None of our sponsors have control over the content of the website, newsletter, apps, Twitter feed or RSS newsfeed.

For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com

Glycosmedia complies with the HONcode standard for trustworthy health information: verify here.


Copyright © 2020 Glycosmedia Partnership

Our mailing address is:
Glycosmedia
9 Woodburn Drive
West Cross
Swansea, West Glamorgan SA3 5TZ
United Kingdom

Add us to your address book


unsubscribe from this list    update subscription preferences 

Email Marketing Powered by Mailchimp